Offering 1 of 5

Before you fund a programme, find out whether it can exist.

A written map of the data available for your question, market by market: which types exist, at what scale and grain, who holds them, what they will release, under what conditions, and how long each approval realistically takes.

Data Landscape Assessment

Why this is worth buying on its own

It stops the expensive failure

The most costly failure in this field is a programme that dies at approval stage in month four, after the budget is committed. A landscape assessment moves that discovery to week three, at a fraction of the cost.

It is the difference between what exists and what is permitted

Almost anyone can tell you a dataset exists. The useful question is whether it can be analysed for your purpose, released across a border, or joined to another source. That answer is not in any catalogue.

It makes an internal proposal defensible

Most evidence programmes are approved or killed on the strength of their feasibility section. This gives you one written by people who have negotiated access in those markets, not one assembled from vendor brochures.

It is reusable

The map does not expire when the project does. It informs the next three questions your team asks, and it is the input to every other offering on this page.

1

Data Landscape Assessment

A written map of the data available for your question, market by market: which types exist, at what scale and grain, who holds them, what they will release, under what conditions, and how long each approval realistically takes..

Timeline
Two to four weeks, depending on the number of markets.
Buy it when
You are deciding whether a regional or multi-market evidence programme is viable at all, you need a defensible feasibility section for an internal proposal, or you are entering a market you have never worked in.
Do not buy it when
You already know your market and your data source and you have one precise question. Go straight to feasibility and cohort scoping, which is offering two.
Deliverables

What you actually receive.

Named, dated and agreed at scoping. Every one of these is a thing you can hold, circulate internally and be held to, not a description of an activity.

A written landscape report

Per market and per data type: what exists, at what scale, at what grain, and covering which slice of the population.

A permissions and governance read

What each source will and will not release, the approval pathway, the bodies involved, and the realistic elapsed time for each step.

A verdict per market

Viable, viable with conditions, or not viable, with the specific constraint that drives each verdict rather than a colour-coded matrix.

A data-type-to-question map

Which of your questions each available source can actually answer, and which it cannot.

A cost and timeline envelope

An indicative shape for what a programme in each market would cost and how long it would take, with the pass-through items named.

A recommendation

Where to start, what to drop, and what to sequence, argued rather than asserted.

How it runs

Four steps, and you see the direction before you see the deck.

1

Scope

We agree the questions, the markets and the therapy area. Half a day, usually one call.

2

Search and assess

We work through the sources in each market, including the ones that are not publicly catalogued, and test them against your questions.

3

Governance read

We map the approval pathway for each viable source, which is where most of the elapsed time in a programme actually sits.

4

Report and walkthrough

A written report, then a working session where your team can argue with it.

Alongside every engagement: weekly updates, methodology agreed before work starts, quality control at every phase, interim reporting rather than a single reveal, and milestones you accept rather than discover.

What it feeds into

Feasibility & Cohort Scoping

The landscape names the market and the data type. Feasibility then tests one precise question against it.

Is this the one you need?

Describe the decision you are trying to make. If a cheaper offering answers it, we will tell you that instead.

De-identified patient-level data and publicly available data, through local alliance partners. De-identification at source. Analysis in-market, under local law. Never identifiable records.